Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Biologic therapy.

Dana Farber/Brigham and Women’s Cancer Center, Boston, MA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Boston, MA
Treatments:Biologic therapyHospital:Dana Farber/Brigham and Women’s Cancer Center
Drugs:Journal:Link
Date:Apr 2011

Description:

Patients:
This phase 2 study involved 40 recurrent glioblastoma patients who had been previously treated. The median patient age was 54 years and 63% were male.

Treatment:
Patients were treated with the biologic therapy agent called AMG 102 (also known as rilotumumab), a monoclonal antibody against the HGF/SF protein that inhibits tumor growth.

Toxicities:
The most severe toxicities were grade 3/4 fatigue and edema (swelling). Nausea, dry skin, and diarrhea were also reported.

Results:
The median overall survival was 6.5 months.

Support:
This study was supported by Amgen, Inc., makers of the study drug.

Correspondence: Dr. Patrick Y. Wen; email: [email protected]



Back